Recently, Fortune China released the 2026 Fortune China 500 list, and SBP Group (1177.HK) was once again included, ranking 19 places higher than last year. This list has long focused on the development scale and comprehensive strength of Chinese enterprises and is an important reference for measuring corporate growth and industry influence. 

This time, a total of 16 companies from the pharmaceutical industry were listed, covering the three major sub-sectors of pharmaceutical commerce, pharmaceuticals, and medical devices. Among the only 6 listed companies in the pharmaceutical sector, 4 companies, including SBP Group, achieved a leap in their rankings. The outstanding performance of innovative pharmaceutical companies reflects the profound transformation of China's pharmaceutical industry from being "scale-driven" to "innovation-driven," and the logic of competition is being rewritten. 

Accelerated Launch of Innovative Products, Building a Diverse Product Matrix

As a leading innovation- and R&D-driven pharmaceutical group in China, SBP Group has leading advantages in four core therapeutic areas: tumor, liver disease/cardiovascular metabolism, respiratory/autoimmune, and surgery/analgesia. In recent years, SBP Group has continuously increased its investment in innovative R&D, and the proportion of revenue from innovative products has continued to rise. Its 2025 performance report shows that SBP Group's full-year revenue from innovative products reached RMB 15.22 billion, with a compound annual growth rate of over 24% and a year-on-year growth rate of 26.2%, becoming the core engine driving the company's consecutive double-digit performance growth. 

Since 2026, SBP Group has launched several innovative products: Rovadicitinib (Anxu®), the world's first-in-class dual-target JAK/ROCK inhibitor, was approved in February, providing a new treatment option for patients with intermediate- to high-risk myelofibrosis; Culmerciclib (Saitanxin®), a CDK2/4/6 inhibitor independently developed by the core enterprise Chia Tai Tianqing, received a new indication for the first-line treatment of HR+/HER2- breast cancer; Naldemedine (Symproic®), the world's first oral selective peripheral μ-opiate receptor antagonist, was successively approved, bringing a new treatment option for patients with opiate-induced constipation (OIC); and Peceleganan (Puyike®), the world's first-in-class ganan-class broad-spectrum anti-infective drug, was also approved for marketing to aid in the treatment of secondary wound infections from burns. 

R&D Investment Continues to Rise, AI Empowers Quality and Efficiency Improvement

The continuous emergence of innovative achievements is supported by long-term R&D investment and the construction of an innovation system. In 2025, SBP Group's full-year R&D expenses reached RMB 5.87 billion, accounting for 18.4% of revenue; in the past 3 years, cumulative R&D expenses exceeded RMB 15 billion. Currently, SBP Group has established ten core technology platforms covering small molecules, monoclonal antibodies, bispecific/multispecific antibodies, ADCs, small interfering RNA (siRNA), and Proteolysis-Targeting Chimera (PROTAC), and has set up R&D centers in multiple locations including Shanghai, Nanjing, Beijing, and Guangzhou. 

Meanwhile, SBP Group is comprehensively advancing its digital strategy, using AI to empower multiple core business scenarios such as drug R&D, clinical medicine, production and quality management, supply chain management, and marketing, continuously enhancing the efficiency of the entire drug lifecycle. Previously, SBP Group, as an independent pharmaceutical company, applied for and was selected for the World Economic Forum's third "AI for Impact Stars" (MINDS) project, receiving high recognition from an internationally authoritative list for SBP Group's AI application capabilities.

 
Deepening Diversified Cooperation Layout, Accelerating the Global Benefit of Innovative Achievements

SBP Group actively promotes global drug accessibility. Through multiple paths such as out-licensing, product in-licensing, investment and M&A, and R&D cooperation, it continuously enhances the international influence of its innovative achievements, gradually forming a dual-track internationalization layout of "going out" and "bringing in."
In recent years, focusing on building innovation capabilities, the company has successively completed strategic mergers and acquisitions of LaNova Medicines and Hygieia, perfecting its innovative technology platform layout. LaNova Medicines possesses a world-leading antibody discovery and ADC technology platform, as well as several potential global FIC/BIC products like LM-302 and LM-108. Its addition will help SBP Group accelerate its innovative layout in the tumor field. Hygieia focuses on the small interfering RNA (siRNA) technology platform and has multiple innovative pipelines in major chronic disease areas such as weight loss/metabolism, cardiovascular and cerebrovascular, and the nervous system, which will further enrich the company's R&D reserves. 

Meanwhile, SBP Group continues to deepen its global cooperation layout: it has out-licensed the overseas rights of its PDE3/4 inhibitor (TQC3721) to AstraZeneca for up to $1.9 billion; reached an out-licensing agreement with Sanofi for Rovadicitinib, setting a new record for a single transaction in the transplant field; and established an exclusive strategic cooperation with GlaxoSmithKline (GSK) for a chronic hepatitis B therapeutic drug. This month, it also in-licensed innovative respiratory products such as Trelegy Ellipta® (Fluticasone Furoate/Umeclidinium/Vilanterol Inhalation Powder, FF/UMEC/VI) and Anoro® (Umeclidinium/Vilanterol Inhalation Powder, UMEC/VI), promoting more innovative treatment solutions to benefit patients. 

SBP Group will continue to adhere to the path of innovative development, supporting global drug accessibility with high-quality R&D investment and systematic innovation construction, responding to unmet clinical needs with more valuable innovative achievements, and bringing more health and well-being to patients worldwide. 

Declaration:
1. This press release is intended to facilitate the communication and exchange of medical information and is for reference by healthcare professionals only. It is not for advertising purposes. 
2. The company does not recommend any drugs and/or indications. 
3. The information contained in this press release is for reference only and cannot replace professional medical guidance in any way, nor should it be considered as a diagnosis or treatment recommendation. If you wish to understand specific disease diagnosis and treatment information, please follow the advice or guidance of a physician or other healthcare professional.